The high correlation between PAI-1 expression and traditional clinical and pathological prognostic parameters like tumor stage, tumor size, nuclear grade and sarcomatoid differentiation may limit the added prognostic utility of this marker in RCC. This evidence concerns the gene SERPINE1 and renal cell carcinoma.